Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

A simultaneous webcast of the call may be accessed by visiting www.endo.com.  In addition, a replay of the webcast will be available until 12:00 a.m. ET on March 1.  The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

Supplemental Financial Information

The following tables provide a reconciliation of our reported (GAAP) statements of operations to our adjusted statements of operations for each of the three months ended Dec. 31, 2009 and Dec. 31, 2008 (Certain prior period amounts have been adjusted to reflect the retrospective adoption of accounting guidance pursuant to ASC 470-20: Debt With Conversion and Other Options (formerly referred to as FSP APB 14-1) and to conform to the current period presentation) (in thousands, except per share data):

    
    
    
    Three Months Ended         Actual
     Dec. 31, 2009            Reported
     (unaudited)               (GAAP)    Adjustments         Adjusted
                              --------   -----------         ---------
    Total Revenues            $391,406             -         $391,406
    Costs and expenses:
      C
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Kannalife Sciences, Inc. ("Kannalife") ... joined its Scientific Advisory Board to assist the Company ... towards the use of cannabinoid therapeutics for the treatment ... forensic pathologist responsible for conducting the full autopsy of ... Fame center for the Pittsburgh Steelers. It was through ...
(Date:3/4/2015)... March 4, 2015  Halyard Health, Inc. (NYSE: ... provided its 2015 outlook and related key planning assumptions. ... Health as we report our fourth quarter results, our ... and CEO. "We executed a smooth separation from Kimberly-Clark ... spin-off. We delivered sales growth and margin improvement in ...
(Date:3/4/2015)... March 4, 2015  ECR Booth #317/Expo C - ... showcasing a full spectrum of X-ray imaging solutions that ... costs, and enable greater patient throughput for manufacturers of ... These solutions are on display at the Annual European ... Austria this week.   "This ...
Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 2Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 3
... Pharmaceuticals, Inc. (NASDAQ: QCOR ) today announced ... on Tuesday, April 26, 2011 after the close of ... conference call and webcast on Tuesday, April 26, 2011 ... discuss results and highlights of the first quarter, as ...
... China Medical Equipment Fair, (CMEF) -- United ... MRI systems in China, is introducing its iuStar100 ... iuStar100 utilizes Samplify,s high-performance, low-power receiver analog front-end ... converter (ADC) to deliver exceptional B-mode and color ...
Cached Medicine Technology:Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011 2United Imaging Healthcare Leverages Samplify's Analog Front-End Solutions to Deliver New Portable Ultrasound System with Superior Image Quality 2
(Date:3/5/2015)... Salt Lake City,Utah (PRWEB) March 05, 2015 ... that manufactures microFET medical dynamometers, ergoFET physical ... acquisition systems with sensors for ergonomics, engineering, ... new microFET Digital Handgrip Dynamometer, available at ... Handgrip was designed to offer healthcare professionals ...
(Date:3/5/2015)... Saint John, New Brunswick (PRWEB) March 05, 2015 ... board to help validate product innovations as the company ... advisory board will be comprised of individuals in the ... approach to working with our clients,” said Elandas CEO ... to grow as a successful organization through our collaborative ...
(Date:3/4/2015)... The emergence of nanotechnology has ... past decade. The pharmaceutical world has witnessed advancements ... the form of liposomes and polymeric nanoparticles that ... safety and efficiency. In the area of ... upon the enhanced permeability and retention (EPR) effect ...
(Date:3/4/2015)... Ultraman Florida is a grueling extreme athletic ... bike, and 52.4 mile run. Christian Isakson finished in ... "This race was awesome and tough," Isakson said. "I ... for supporting me through every part of this brutal ... of 40 select participants invited from across the United ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 TROY Healthcare ... software, which provides the ultimate level of security for ... the Hilton Houston Plaza Medical Center located at 6633 ... , Beginning at 7 AM, TROY Healthcare Solutions will ... Healthcare Solutions will offer brief presentations each hour to ...
Breaking Medicine News(10 mins):Health News:New Handgrip Strength Tester Receives Rave Reviews At Physical Therapy Conference 2Health News:Elandas Creates Advisory Board to Help Guide Innovation 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3
... be detected earlier using a computer-assisted detection system ( ... a computer-based analysis designed to find breast abnormalities. // ... as tiny white specks on mammography film. These tiny ... reviewed the cases of 519 patients with breast cancer. ...
... second-leading cause of cancer death in men and kills nearly ... one in six, is higher than the one in eight ... shows the rate of rise in prostate-specific antigen levels, or ... indicator of eventual death from prostate cancer than the actual ...
... saying that the gene known as “mighty mouse” might ... gene arose when a German neurologist , stumbled // on ... tests revealed the child had a mutation in his myostatin ... protein, which is known to regulate muscle growth. So far ...
... New research shows a significant improvement in treatment for a ... I seminoma is typically treated by // removal of the ... developing a second cancer in another organ up to 20 ... receive a single course of the drug carboplatin and more ...
... found to boost the immune system and help fight off ... on children already in the hospital with severe pneumonia// and ... children with severe pneumonia recover quicker . ,The study ... About half received 20 milligrams of zinc per day while ...
... for cosmetic purposes to erase the signs of aging. However ... toxin is being used to treat a chronic condition known ... of the stomach after a meal. It may be for ... by the patient.The condition causes a person to feel full ...
Cached Medicine News:
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
Bivona® stylets are manufactured of malleable stainless steel wire. The length can be adjusted by sliding the attached silicone stopper. The Blue Line® tracheal tube introducer (bougie) is de...
... manufactures two groups of flexible lighting products. ... non-sterile in three different sizes 5", 10", ... portion of the light). These lights are ... is needed., ,The second group of ...
Medicine Products: